Testosterone Therapy After Radical Prostatectomy: Insights From a Systematic Review and Meta-Analysis.
Testosterone therapy after prostatectomy associated with low biochemical recurrence rate.
Testosterone Therapy After Radical Prostatectomy: Insights From a Systematic Review and Meta-Analysis.
The safety of testosterone therapy (testosterone therapy) in men with a history of prostate cancer (prostate cancer) remains controversial, particularly after interventions for prostate cancer including radical prostatectomy (radical prostatectomy).
To systematically review and meta-analyze the risk of biochemical recurrence (biochemical recurrence) in hypogonadal men treated with testosterone therapy following radical prostatectomy for prostate cancer.
A systematic search of Medline was conducted from 1969 to July 2025 according to PRISMA and MOOSE guidelines.
recurrence stayed rare, testosterone did not appear to reawaken the cancer
In studies with untreated controls, testosterone therapy was associated with a significantly lower biochemical recurrence risk.
Limited data suggested improvements in erectile function and quality of life.
Funnel plot analysis indicated no publication bias.
Testosterone therapy after radical prostatectomy appears to be associated with a limited risk of biochemical recurrence in hypogonadal men with prostate cancer.
However, the absence of randomized controlled trials and incomplete reporting of key clinical variables preclude definitive conclusions.
Larger, well-designed prospective studies are warranted to confirm these findings and clarify the long-term safety profile of the use of testosterone replacement therapy in this setting.